Key Takeaways
- A deliberately soft quarter: Revenue fell 26% YoY to ₹290.3 crore as the company chose to forgo new DDC MSAs and wait for commercial contracts, while Canadian semaglutide approvals slipped. Management calls this the trough before the CSA ramp.
- FY28 guidance held firm: The $400 mn revenue, $160 mn EBITDA target was reiterated on an organic basis, with the exit run rate of Q4 FY27 expected to closely approximate those numbers.
- The demand signal is unambiguously strong: Every customer has revised forecasts upward, the biologics funnel is at a historic high, and capacity expansion of over ₹700 crore is underway to meet expected commercial volumes.
- The balance sheet is being deliberately stretched for launch: Inventory is building (customer-backed), net debt will rise toward 1.5x EBITDA, and a four-month shutdown at the Bangalore sterile facility will temporarily constrain output, all in service of the coming commercial wave.
- What to watch next quarter: The Canadian approval (expected between now and May), the pace of emerging-market COPP approvals in April, and any further adjustments to take-or-pay contract terms with key customers.
The Revenue Trough: Why Q3 Was Soft
- The DDC decision: Management deliberately chose not to accept new DDC MSAs, prioritizing capacity for higher-value commercial sales. Since DDC carries very significant EBITDA margins, the revenue drop flowed almost entirely to the bottom line.
- The approval delay: Semaglutide approval delays for customers in Canada pushed out the expected transition from MSAs to CSAs, prolonging the period of lower-margin MSA output without the offset of new MSA signings.
- The capacity math: The 4 crore headline capacity does not translate to 4 crore output because commercial campaigns run 6 batches in 7 days while MSAs run only 2 batches in 7 days, so output during the MSA phase is less than a third of commercial levels.
- The shutdown: A four-month shutdown at the Bangalore sterile facility (not the flagship DDC site) is converting capacity toward long-acting injectables, high-viscosity pre-filled syringes, and lyophilization, adding near-term pressure for medium-term capability gains.
- The working capital build: Inventory has been built up for significant upcoming semaglutide launches, all customer-backed with advances or firm purchase orders, and is expected to normalize gradually over FY27.
Neeraj Sharma: "what is really heartening for us, and it should be also for our investors, is that the underlying demand of our business remains absolutely robust."
The Commercial Ramp: Approvals, Markets & Timing
- Canadian approval: Based on partner guidance, approval is estimated anytime between now and May, with other filers from the facility following a little later. This is the single most important near-term catalyst.
- Indian market: Products will be available at market opening through partners, but India is not a focus market due to severe competitive intensity.
- Emerging markets: 80 to 100 countries open up around end of March, with the COPP certificate expected in early April, after which a flurry of approvals is expected for partners across emerging markets.
- Supply start: Supplies will begin in very short order after approvals come, though volume ramp-up will take time.
- Batch size scale-up: The company is working with partners to increase batch size from 200 liters to 500 liters, which would make output 2.5x within the same time, subject to regulatory approvals.
- Pricing is geography-agnostic: OneSource's pricing to customers is fixed based on volumes, not volume tiers or end markets, so the economics are the same whether the customer sells in Canada, Brazil, or Saudi Arabia.
The FY28 Bridge: How Management Plans to Get There
- The exit-rate logic: Management expects Q4 FY27's analyzed exit run rate for both revenues and EBITDA to be a good reflection of near-close FY28 guidance numbers, implying a steep ramp through FY27.
- H2 significantly stronger: FY27 will mark the beginning of material CSA revenues, with H2 significantly stronger than H1, and sequential quarter-after-quarter improvement once major-market approvals come and supplies start.
- Customer forecast alignment: Every single customer has revised forecasts upward, providing the demand-side confidence behind the guidance.
- Capacity coming online: By end of FY27, almost 20 crore (odd) installed capacity will be available, with enhancements at regular intervals through the year. For most customers and markets, no additional regulatory timelines are expected because many changes are annual reportable.
- The debt path: On the base business (₹50 crore, ₹20 crore EBITDA), the company expects to be debt-free by FY28, even as near-term net debt rises toward 1.5x EBITDA to fund capex and potential US and Europe beachhead investments.
Arun Kumar: "We remain extremely confident on our ability to achieve these targets, and I will explain why we believe so."
Biologics: The Optionality That Is Becoming Real
- The tailwinds: The Biosecure Act (regardless of final form) is accelerating geographical diversification, with US, Japanese, and European companies looking at India and OneSource. New FDA guidelines mean most biosimilars no longer require Phase III clinical trials, cutting development cost from roughly ₹100–120 crore to ₹30–40 crore and timeline from eight to nine years to roughly half.
- The funnel: RFPs are almost 4x year-end levels, and the funnel is at a historic high.
- Customer onboarding: A U.S.-based biosimilar major was onboarded during the quarter, with active discussions ongoing with multiple European players.
- The pricing model: OneSource's pricing is fixed based on volumes, not end markets, so the biologics opportunity carries the same margin structure as the core business.
Neeraj Sharma: "we are most excited about our nascent biologics business, which has benefited from some very strong tailwinds, both from the new FDA guidelines on biosimilars, as well as the passage of the Biosecure Act in the U.S."
Partnership Philosophy & Contract Discipline
- Flexibility as strategy: Management is being flexible with key customers on take-or-pay agreements because delays are due to regulatory issues, not demand forecast gaps or willingness to buy. This builds long-term partnerships.
- But not universal: Not all customers get flexibility, some are being held to the clauses strongly, showing selective rather than blanket accommodation.
- Inventory risk sits with customers: As a CDMO, all inventory risk belongs to the customers, and the inventory build-up is backed by advances or firm purchase orders.
- The oncology win: A contract was signed with one of the largest companies for a branded product approved through the NDA route, with only one other competitor in the market. Launch is expected next quarter.
Neeraj Sharma: "What we gain from being acting like partners and not like mercenary CDMOs is to really gain a long term partnership with the customers..."
Other Businesses & Operational Updates
- Soft gelatin: Secured approval for the first oncology asset (an NDA), partnered with one of the top 10 US generic companies.
- Injectables: Customers continue to gain share for existing products and add new projects to the pipeline.
- Acquisition: Application for two injectable facilities has been submitted to the Stock Exchange, with final regulatory approvals anticipated by Q3 FY27.
- Quality record: Year-to-date, 36 inspections from regulators and customers, with a stellar recent FDA inspection at the Bangalore sterile facility and a very good inspection at the flagship DDC site.
- Credit rating: Two notches of upgrades leading to four notch upgrades overall, with interest cost now 200 bps lower versus last year and an effective interest rate below 9%.
- Oral GLP-1 impact: Oral GLP-1s will have a role for needle-phobic patients, but efficacy differences mean injectables remain important, limiting substitution risk to the core franchise.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY28 revenue & EBITDA | $400 mn revenue, $160 mn EBITDA, organically | FY28 |
| Exit run rate as proxy | Q4 FY27 exit run rate to closely approximate FY28 guidance | Q4 FY27 |
| Canadian approval | Based on partner guidance, approval expected | Between now and May |
| Emerging market COPP | Certificate expected, triggering flurry of partner approvals | First few days of April |
| Capacity expansion | Almost 20 crore installed capacity available | By end of FY27 |
| Net debt ceiling | Less than 1.5x of EBITDA | Near-term |
| Base business debt-free | On ₹50 cr / ₹20 cr EBITDA base business | By FY28 |
| Acquisition close | Final regulatory approvals for two injectable facilities | Q3 FY27 |
| Oncology launch | Branded NDA product with one competitor | Next quarter |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹290.3 cr, 26% YoY decline and down ~US$10 mn QoQ |
| EBITDA | ₹17.3 cr, declined by roughly the same amount as the revenue shortfall QoQ |
| Adjusted PAT (loss) | ₹(47.2) cr |
| Adjusted diluted EPS | ₹(4.1) per share |
| FY28 revenue guidance | $400 mn, reiterated, organic, excludes inorganic accretions |
| FY28 EBITDA guidance | $160 mn, reiterated |
| Capex plan | Over ₹700 cr to increase capacities, progressing well |
| Capex committed | ~75% of total planned ₹10 cr capex investment spend for flagship site |
| Customer advances | ~₹250 cr held as advances from customers pre-booking capacities |
| Workforce addition | ~300 new FTEs added year-to-date at flagship site, doubling workforce |
| Biologics RFP growth | ~4x versus end of last year |
| Effective interest rate | Below 9%, 200 bps lower versus last year |
| Net debt-to-EBITDA guidance | Below 1.5x, near-term peak guidance |
| Regulatory and customer inspections | 36 year-to-date |
| DDC base capacity utilization (peak) | 70–75% typical for sterile injectables at full commercial scale |